Retinitis Pigmentosa Clinical Trials

48 recruitingLast updated: June 18, 2026

There are 48 actively recruiting retinitis pigmentosa clinical trials across 25 countries. Studies span Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 3. Top locations include Dallas, Texas, United States, Portland, Oregon, United States, Paris, France. Updated daily from ClinicalTrials.gov.


Retinitis Pigmentosa Trials at a Glance

48 actively recruiting trials for retinitis pigmentosa are listed on ClinicalTrialsFinder across 6 cities in 25 countries. The largest study group is Phase 1 with 15 trials, with the heaviest enrollment activity in Dallas, Portland, and Paris. Lead sponsors running retinitis pigmentosa studies include Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Columbia University, and Frontera Therapeutics.

Browse retinitis pigmentosa trials by phase

Treatments under study

About Retinitis Pigmentosa Clinical Trials

Looking for clinical trials for Retinitis Pigmentosa? There are currently 33 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Retinitis Pigmentosa trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Retinitis Pigmentosa clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 48 trials

Recruiting

Cell Collection to Study Eye Diseases

Retinal DegenerationRetinitis PigmentosaRetinal Disease+1 more
National Eye Institute (NEI)930 enrolled1 locationNCT01432847
Recruiting

Retinal Imaging in Patients With Inherited Retinal Degenerations

Retinitis Pigmentosa
University of California, San Francisco400 enrolled1 locationNCT00254605
Recruiting

Rod and Cone Mediated Function in Retinal Disease

Stargardt's DiseaseRetinal DegenerationRetinitis Pigmentosa
National Eye Institute (NEI)500 enrolled1 locationNCT02617966
Recruiting

Inherited Retinal Degenerative Disease Registry

Retinitis PigmentosaBatten DiseaseLeber Congenital Amaurosis+25 more
Foundation Fighting Blindness20,000 enrolled1 locationNCT02435940
Recruiting

Adaptive Optics Imaging of Outer Retinal Diseases

Age-Related Macular DegenerationRetinal DegenerationRetinitis Pigmentosa+7 more
Food and Drug Administration (FDA)100 enrolled2 locationsNCT05355415
Recruiting

Observational Study to Investigate the Short-term Effects of Transcorneal Electrical Stimulation on Visual Performance

Retinitis pigmentosa (RP)Cone-Rod DystrophyUsher Syndrome
Okuvision GmbH30 enrolled1 locationNCT07548944
Recruiting

High Resolution Retinal Imaging

Geographic AtrophyAge-Related Macular DegenerationRetinitis Pigmentosa+2 more
University of Pennsylvania600 enrolled1 locationNCT01866371
Recruiting
Phase 2

A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa

Retinitis Pigmentosa
Kiora Pharmaceuticals, Inc.36 enrolled5 locationsNCT06628947
Recruiting

Natural History Study of Patients With EYS-Associated RP

Retinitis PigmentosaEye Diseases
Sensor Technology for Deafblind45 enrolled1 locationNCT07228793
Recruiting
Not Applicable

Impact of Capsular Tension Ring on Intraocular Lens Position in Retinitis Pigmentosa Cataract Patients

Retinitis pigmentosa (RP)Cataract
Zhongshan Ophthalmic Center, Sun Yat-sen University88 enrolled3 locationsNCT07126470
Recruiting
Phase 1Phase 2

A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa

Retinitis Pigmentosa
Sumitomo Pharma America, Inc.12 enrolled2 locationsNCT06891885
Recruiting

Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants

Retinitis PigmentosaInherited Retinal Degeneration
Jaeb Center for Health Research1,500 enrolled36 locationsNCT05589714
Recruiting
Phase 2

Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)

Retinitis Pigmentosa
jCyte, Inc60 enrolled14 locationsNCT06912633
Recruiting
Phase 1Phase 2

A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)

Retinitis pigmentosa (RP)Retinal DegenerationPrimary Photoreceptor Disease+6 more
BlueRock Therapeutics54 enrolled4 locationsNCT06789445
Recruiting
Not Applicable

Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration

Retinitis pigmentosa (RP)Stargardt DiseaseInherited Retinal Degeneration
Science Corporation5 enrolled1 locationNCT07266584
Recruiting
Phase 2

Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

deaf-blindRetinitis pigmentosa (RP)Retinal Disease+4 more
Laboratoires Thea81 enrolled27 locationsNCT06627179
Recruiting
Early Phase 1

Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients

Retinitis Pigmentosa
Zhongmou Therapeutics12 enrolled1 locationNCT06292650
Recruiting

Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)

X-linked RetinoschisisRetinitis PigmentosaStargardt Disease+3 more
Ray Therapeutics, Inc.25 enrolled1 locationNCT07502664
Recruiting
Phase 3

A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa

Retinitis Pigmentosa
Janssen Pharmaceutical K.K.4 enrolled1 locationNCT05926583
Recruiting
Phase 2

A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa

X-Linked Retinitis Pigmentosa (XLRP)
Beacon Therapeutics10 enrolled6 locationsNCT07174726